Skip to main content

Advertisement

Contraception hormonale masculine par les androgènes seuls. Acquis et perspectives

Hormonal male contraception by androgens only. Present and future

Article metrics

  • 716 Accesses

  • 1 Citations

Résumé

Il existe en France une demande de contraception masculine. Il est possible d’y répondre en utilisant des stéroïdes (androgènes, progestatifs). Des études effectuées dans plusieurs pays, dont la France, ont confirmé l’efficacité contraceptive de ces traitements — équivalente à celle des contraceptions féminines. On peut utiliser les androgènes seuls qui pourraient être indiqués, dans des conditions bien définies, à des couples pour lesquels les méthodes traditionnelles de contraception ne conviennent pas. Deux obstacles limitent un large usage des androgènes: les risques d’un état d’hyperandrogénie prolongé et le mode d’administration par injection. L’association de progestatifs à de faibles doses d’androgènes devrait réduire ces inconvénients.

Abstract

There is in France a demand for male contraception. It is possible to respond it using steroids (androgens, progestins). Studies in several countries, including France, have confirmed the contraceptive efficacy of these treatments — equivalent to female contraception. Androgens may be indicated, in defined conditions, to couples for which traditional methods of contraception are not suitable. Two obstacles limit widespread use of androgens: risk of a prolonged state of hyperandrogenism and mode of administration by injection. The combination of progestins to low doses of androgens should reduce these drawbacks.

Références

  1. 1.

    Soufir JC, Jouannet P, Soumah A (1983) Male contraception: effect on sperm production and gonadotrophin secretion of percutaneous testosterone alone or combined with oral medroxyprogesterone acetate. Society for the Study of Fertility, Manchester

  2. 2.

    McLachlan RI, McDonald J, Rushford D, et al (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 62:73–78

  3. 3.

    Guérin JF, Rollet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11:187–199

  4. 4.

    Lee A, Rubinow K, Clark RV, et al (2012) Pharmakokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism. J Androl 33:420–426

  5. 5.

    Behre HM, Baus S, Kliesch S, et al (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394–2403

  6. 6.

    Knuth UA, Behre H, Belkien L, et al (1985) Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril 44:814–821

  7. 7.

    Heller CG, Nelson WO, Hill IB, et al (1950) Improvement in spermatogenesis following depression of human testis with testosterone. Fertil Steril 1:415–422

  8. 8.

    Heckel NJ, Mc Donald JH (1952) The effects of testosterone propionate upon spermatogenetic function of the human testis. Ann NY Acad Sci 55:725–733

  9. 9.

    Steinberger E (1977) Effect of chronic administration of testosterone enanthate on sperm production and plasma testosterone, follicle stimulating hormone levels: preliminary evaluation of a possible male contraceptive. Fertil Steril 12:1320–1328

  10. 10.

    Capell PT, Paulsen CA (1972) The effect of exogenous testosterone upon serum FSH and LH concentrations in normal males. Contraception 6:135–143

  11. 11.

    Paulsen CA, Noonan E, Rost E, Meriggiola MC (1992) Studies on the induction of azoospermia/oligozoospermia using testosterone as a contraceptive agent in normal men. ASRM Annual meeting, Poster O-112

  12. 12.

    Swerdloff RS, Palacios A, McClure RS, et al (1978) Male contraception: clinical assesment of chronic administration of testosterone enanthante. Int J Androl suppl 2:731

  13. 13.

    Swerdloff RS, Campfield LA, Palacios A, McClure RD (1979) Suppression of human spermatogenesis by depot androgen: potential for male contraception. J Steroid Biochem 11:663–670

  14. 14.

    WHO. Task Force on methods for the regulation of male fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955–959

  15. 15.

    WHO. Task Force on methods for the regulation of male fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821–829

  16. 16.

    Barfield A, Melo J, Coutinho F, et al (1979) Pregnancies associated with sperm concentration below 10 millions/ml in clinical studies of potential male contraceptive method monthly depot acetate medroxyprogesterone acetate and testosterone esters. Contraception 20:121–127

  17. 17.

    Wu FC (1996) Male Contraception. Bailleres Clin Obstet Gynaecol 10:1–23

  18. 18.

    Handelsman DJ, Farley TM, Peregoudov A, et al (1995) Factors in non uniform induction of azoospermia by testosterone enanthate in normal men. Fertil Steril 63:125–133

  19. 19.

    Eckardstein SV, Schmidt A, Kamischke A, et al (2002) CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 57:647–655

  20. 20.

    Anderson RA, Wallace AM, Wu FC (1996) Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 81:902–908

  21. 21.

    Hikim AP, Wang C, Lue Y, et al (1998) Spontaneous germ cell apoptosis in humans: evidence for ethnic differences in the susceptibility of germ cells to programmed cell death. J Clin Endocrinol Metab 83:152–156

  22. 22.

    Zhang GY, Gu YQ, Wang XH, et al (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 84:3642–3647

  23. 23.

    Gu YQ, Wang XH, Xu D, et al (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562–568

  24. 24.

    Gu Y, Liang X, Wu W, et al (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94:1910–1915

  25. 25.

    Nieschlag E, Vorona E, Wenk M, et al (2011) Hormonal male contraception in men with normal and subnormal semen parameters. Int J Androl 34:556–567

  26. 26.

    Martin CW, Anderson RA, Cheng L, et al (2000) Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod 15:637–645

  27. 27.

    Page ST, Amory JK, Anawalt BD, et al (2006) Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 91:4374–4380

  28. 28.

    Turner L, Conway AJ, Jimenez M, et al (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659–4667

  29. 29.

    Soufir JC, Meduri G, Ziyyat A (2011) Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod 26:1708–1714

  30. 30.

    Aaltonen P, Amory JK, Anderson RA, et al (2007) 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. J Androl 28:362–363

Download references

Author information

Correspondence to J. -C. Soufir.

Rights and permissions

Reprints and Permissions

About this article

Mots clés

  • Contraception masculine
  • Androgènes
  • Progestatifs
  • Spermatogénèse
  • Gonadotrophines

Keywords

  • Male contraception
  • Androgens
  • Progestins
  • Spermatogenesis
  • Gonadotrophins